Apolipoprotein A-I(R151C)Paris is defective in activation of lecithin:cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux-Reference-Cited by-同舟云学术

Apolipoprotein A-I(R151C)Paris is defective in activation of lecithin:cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux

Published:1999-08 Issue:8 Volume:77 Page:614-622
ISSN:0946-2716
Container-title:Journal of Molecular Medicine
language:en
Short-container-title:J Mol Med

Author:

Daum Ulrike,Langer Claus,Duverger Nicolas,Emmanuel Florence,Benoit Patrick,Patrice Denèfle Patrice,Chirazi Ali,Cullen Paul,Haydn Pritchard P.,Bruckert Eric,Assmann Gerd,von Eckardstein Arnold

Publisher

Springer Science and Business Media LLC

Subject

Genetics (clinical),Drug Discovery,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s001099900034.pdf

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma monomeric ApoA1 and high‐density lipoprotein bound ApoA1 are markedly decreased and associated with low levels of lipophilic antioxidants in sickle cell disease: A potential new pathway for therapy;European Journal of Haematology;2024-08-20

2. Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease;Journal of Controlled Release;2024-03

3. HDL Dysfunction Caused by Mutations in apoA-I and Other Genes that are Critical for HDL Biogenesis and Remodeling;Current Medicinal Chemistry;2019-05-21

4. Structural Insights into High Density Lipoprotein: Old Models and New Facts;Frontiers in Pharmacology;2016-01-12

5. Genetic Determinants of HDL Metabolism;Current Medicinal Chemistry;2014-07-31